Peringatan Keamanan

Symptoms of overdose include drowsiness, loss of or impaired muscle coordination, nausea, visual disturbance, and, at very high doses, coma.

Ethotoin

DB00754

small molecule approved

Deskripsi

Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges. Ethotoin is no longer commonly used.

Struktur Molekul 2D

Berat 204.2252
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 3 to 9 hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Fairly rapidly absorbed, however, the extent of oral absorption is not known.

Metabolisme

Hepatic. The drug exhibits saturable metabolism with respect to the formation of N-deethyl and p-hydroxyl-ethotoin, the major metabolites.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data
  • 1. Take after a meal. This may reduce gastrointestinal upset.

Interaksi Obat

889 Data
Aripiprazole The metabolism of Aripiprazole can be increased when combined with Ethotoin.
Aripiprazole lauroxil The metabolism of Aripiprazole lauroxil can be increased when combined with Ethotoin.
Buprenorphine Ethotoin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.
Hydrocodone Ethotoin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.
Magnesium sulfate The therapeutic efficacy of Ethotoin can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Ethotoin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Ethotoin may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.
Mirtazapine Ethotoin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.
Orphenadrine Ethotoin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Ethotoin may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Pramipexole Ethotoin may increase the sedative activities of Pramipexole.
Ropinirole Ethotoin may increase the sedative activities of Ropinirole.
Rotigotine Ethotoin may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Ethotoin.
Sodium oxybate Ethotoin may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Ethotoin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.
Thalidomide Ethotoin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Ethotoin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Mefloquine The therapeutic efficacy of Ethotoin can be decreased when used in combination with Mefloquine.
Mianserin The therapeutic efficacy of Ethotoin can be decreased when used in combination with Mianserin.
Orlistat Orlistat can cause a decrease in the absorption of Ethotoin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Topotecan Ethotoin may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Ethotoin.
Ifosfamide The metabolism of Ifosfamide can be increased when combined with Ethotoin.
Perampanel The metabolism of Perampanel can be increased when combined with Ethotoin.
R,S-Warfarin alcohol The metabolism of R,S-Warfarin alcohol can be increased when combined with Ethotoin.
S,R-Warfarin alcohol The metabolism of S,R-Warfarin alcohol can be increased when combined with Ethotoin.
Dicoumarol The therapeutic efficacy of Dicoumarol can be increased when used in combination with Ethotoin.
Phenindione The therapeutic efficacy of Phenindione can be increased when used in combination with Ethotoin.
Warfarin The therapeutic efficacy of Warfarin can be increased when used in combination with Ethotoin.
Phenprocoumon The therapeutic efficacy of Phenprocoumon can be increased when used in combination with Ethotoin.
Acenocoumarol The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Ethotoin.
4-hydroxycoumarin The therapeutic efficacy of 4-hydroxycoumarin can be increased when used in combination with Ethotoin.
Coumarin The therapeutic efficacy of Coumarin can be increased when used in combination with Ethotoin.
(R)-warfarin The therapeutic efficacy of (R)-warfarin can be increased when used in combination with Ethotoin.
Ethyl biscoumacetate The therapeutic efficacy of Ethyl biscoumacetate can be increased when used in combination with Ethotoin.
Fluindione The therapeutic efficacy of Fluindione can be increased when used in combination with Ethotoin.
Clorindione The therapeutic efficacy of Clorindione can be increased when used in combination with Ethotoin.
Diphenadione The therapeutic efficacy of Diphenadione can be increased when used in combination with Ethotoin.
Tioclomarol The therapeutic efficacy of Tioclomarol can be increased when used in combination with Ethotoin.
(S)-Warfarin The therapeutic efficacy of (S)-Warfarin can be increased when used in combination with Ethotoin.
Tetracosactide The risk or severity of liver damage can be increased when Tetracosactide is combined with Ethotoin.
Ethanol Ethotoin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Ethotoin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.
Fluvoxamine The risk or severity of adverse effects can be increased when Ethotoin is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Ethotoin is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Ethotoin is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Ethotoin is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Ethotoin is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Ethotoin is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Ethotoin is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Ethotoin is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Ethotoin is combined with Escitalopram.
Zimelidine The risk or severity of adverse effects can be increased when Ethotoin is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Ethotoin is combined with Dapoxetine.
Desvenlafaxine The risk or severity of adverse effects can be increased when Ethotoin is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Ethotoin is combined with Seproxetine.
Indalpine The risk or severity of adverse effects can be increased when Ethotoin is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Ethotoin is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Ethotoin is combined with Alaproclate.
Erlotinib The serum concentration of Erlotinib can be decreased when it is combined with Ethotoin.
Cyproheptadine The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Ethotoin.
Amoxapine The risk or severity of CNS depression can be increased when Amoxapine is combined with Ethotoin.
Propiomazine The risk or severity of CNS depression can be increased when Ethotoin is combined with Propiomazine.
Maprotiline The risk or severity of CNS depression can be increased when Ethotoin is combined with Maprotiline.
Desipramine The risk or severity of CNS depression can be increased when Ethotoin is combined with Desipramine.
Pizotifen The risk or severity of CNS depression can be increased when Ethotoin is combined with Pizotifen.
Dosulepin The risk or severity of CNS depression can be increased when Ethotoin is combined with Dosulepin.
Cocaine The risk or severity of methemoglobinemia can be increased when Ethotoin is combined with Cocaine.
Quetiapine The risk or severity of CNS depression can be increased when Ethotoin is combined with Quetiapine.
Amitriptyline The risk or severity of CNS depression can be increased when Amitriptyline is combined with Ethotoin.
Imipramine The risk or severity of CNS depression can be increased when Imipramine is combined with Ethotoin.
Doxepin The risk or severity of CNS depression can be increased when Ethotoin is combined with Doxepin.
Clozapine The serum concentration of Clozapine can be decreased when it is combined with Ethotoin.
Nortriptyline The risk or severity of CNS depression can be increased when Nortriptyline is combined with Ethotoin.
Quinidine The therapeutic efficacy of Ethotoin can be decreased when used in combination with Quinidine.
Zopiclone The risk or severity of adverse effects can be increased when Ethotoin is combined with Zopiclone.
Botulinum toxin type B The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Ethotoin.
Botulinum toxin type A The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Ethotoin.
Tryptophan The risk or severity of CNS depression can be increased when Tryptophan is combined with Ethotoin.
Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.
Lorazepam The risk or severity of CNS depression can be increased when Lorazepam is combined with Ethotoin.
Ethchlorvynol The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Ethotoin.
Succinylcholine The risk or severity of CNS depression can be increased when Succinylcholine is combined with Ethotoin.
Reserpine The risk or severity of CNS depression can be increased when Reserpine is combined with Ethotoin.
Enflurane The risk or severity of CNS depression can be increased when Enflurane is combined with Ethotoin.
Temazepam The risk or severity of CNS depression can be increased when Temazepam is combined with Ethotoin.
Reboxetine The risk or severity of CNS depression can be increased when Reboxetine is combined with Ethotoin.
Butabarbital The risk or severity of CNS depression can be increased when Butabarbital is combined with Ethotoin.
Butalbital The risk or severity of CNS depression can be increased when Butalbital is combined with Ethotoin.
Topiramate The risk or severity of CNS depression can be increased when Topiramate is combined with Ethotoin.
Clemastine The risk or severity of CNS depression can be increased when Clemastine is combined with Ethotoin.

Target Protein

Sodium channel protein type 5 subunit alpha SCN5A
Nuclear receptor subfamily 1 group I member 2 NR1I2

Referensi & Sumber

Synthesis reference: Close, W.J.; U.S. Patent 2,793,157; May 21, 1957; assigned to Abbott Laboratories.
Artikel (PubMed)
  • PMID: 13317788
    SCHWADE ED, RICHARDS RK, EVERETT GM: Peganone, a new antiepileptic drug. Dis Nerv Syst. 1956 May;17(5):155-8.

Contoh Produk & Brand

Produk: 3 • International brands: 2
Produk
  • Peganone
    Tablet • 250 mg/1 • Oral • US • Approved
  • Peganone
    Tablet • 250 mg/1 • Oral • US • Approved
  • Peganone
    Tablet • 250 mg/1 • Oral • US • Approved
International Brands
  • Accenon — Dainippon Sumitomo
  • Pegoanone

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul